Literature DB >> 18831513

Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation.

Caroline Masserot1, Régis Peffault de Latour, Vanderson Rocha, Thierry Leblanc, Arnaud Rigolet, Francis Pascal, Anne Janin, Jean Soulier, Eliane Gluckman, Gérard Socié.   

Abstract

BACKGROUND: Fanconi anemia (FA) is a chromosomal instability disorder with a very high risk of developing head and neck squamous cell carcinoma (HNSCC), most notably after hematopoietic stem cell transplantation (HSCT).
METHODS: In the current study, the authors reported 13 cases of HNSCC in FA patients who underwent HSCT at the Saint Louis Hospital between 1976 and 2007.
RESULTS: The median age of the patients at time of HSCT was 9.7 years. All patients received irradiation-based conditioning before HSCT and all developed extensive chronic graft versus host disease (GVHD). HNSCC was diagnosed at a median interval of 10 years after HSCT, mainly in numerous sites within the oral cavity (11 patients). Lymph node involvement was diagnosed in 4 patients. The TNM classification was: T1 in 6 patients, T2 in 2 patients, T3 in 2 patients, and T4 in 3 patients. Treatment was comprised of surgery in 10 patients, with clear surgical margins reported in 7 (including cervical lymph node dissection in 6 patients). Surgery was performed in addition to other treatments in only 2 patients (radiotherapy or cryotherapy). For the remaining 3 patients, treatment consisted in radiotherapy (2 patients) or chemotherapy (1 patient). Disease progression while receiving therapy was observed in 5 patients and 5 other patients developed disease recurrence between 3.5 and 23.7 months after treatment. Death occurred in 11 patients. At the time of last follow-up, only 2 patients were alive without any disease between 9 and 23 months after diagnosis.
CONCLUSIONS: HNSCC developing in FA patients after HSCT is associated with a very poor prognosis. A systematic surveillance of the oral cavity is essential to permit early surgery, which to the authors' knowledge remains the only curative treatment for a minority of patients. It is very important to attempt to prevent this cancer by reducing chronic GVHD and using conditioning without irradiation.

Entities:  

Mesh:

Year:  2008        PMID: 18831513     DOI: 10.1002/cncr.23954

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  37 in total

1.  GS-nitroxide (JP4-039)-mediated radioprotection of human Fanconi anemia cell lines.

Authors:  Mark E Bernard; Hyun Kim; Hebist Berhane; Michael W Epperly; Darcy Franicola; Xichen Zhang; Frank Houghton; Donna Shields; Hong Wang; Christopher J Bakkenist; Marie-Celine Frantz; Erin M Forbeck; Julie P Goff; Peter Wipf; Joel S Greenberger
Journal:  Radiat Res       Date:  2011-09-22       Impact factor: 2.841

Review 2.  Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines.

Authors:  K Scheckenbach; M Wagenmann; M Freund; J Schipper; H Hanenberg
Journal:  Klin Padiatr       Date:  2012-04-13       Impact factor: 1.349

3.  Natural history and management of Fanconi anemia patients with head and neck cancer: A 10-year follow-up.

Authors:  David I Kutler; Krupa R Patel; Arleen D Auerbach; Jennifer Kennedy; Francis P Lach; Erica Sanborn; Marc A Cohen; William I Kuhel; Agata Smogorzewska
Journal:  Laryngoscope       Date:  2015-10-20       Impact factor: 3.325

4.  Programmable bio-nanochip-based cytologic testing of oral potentially malignant disorders in Fanconi anemia.

Authors:  P N Floriano; T Abram; L Taylor; C Le; H Talavera; M Nguyen; R Raja; A Gillenwater; J McDevitt; N Vigneswaran
Journal:  Oral Dis       Date:  2015-04-06       Impact factor: 3.511

5.  Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: Series of 9 cases and review of the literature.

Authors:  Thomas H Beckham; Jonathan Leeman; Chiaojung Jillian Tsai; Nadeem Riaz; Eric Sherman; Bhuvanesh Singh; Nancy Lee; Sean McBride; Daniel S Higginson
Journal:  Head Neck       Date:  2019-01-11       Impact factor: 3.147

6.  Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia.

Authors:  Asha Pillai; Christine Hartford; Chong Wang; Deqing Pei; Jie Yang; Ashok Srinivasan; Brandon Triplett; Mari Dallas; Wing Leung
Journal:  Pediatr Transplant       Date:  2011-07-15

7.  Hypersensitivity to chemoradiation in FANCA carrier with cervical carcinoma-A case report and review of the literature.

Authors:  Igor Sirák; Zuzana Šinkorová; Mária Šenkeříková; Jiří Špaček; Jan Laco; Hana Vošmiková; Stanislav John; Jiří Petera
Journal:  Rep Pract Oncol Radiother       Date:  2014-12-05

8.  p53 phosphorylation and TP53 copy-number alterations in chronic graft-versus-host oral lichen preceding squamous cell carcinoma.

Authors:  Maxime Battistella; Wendy Cuccuini; Morad Elbouchtaoui; Christophe Leboeuf; Louis-François Plassa; Fatiha Bouhidel; Arnaud Rigolet; Véronique Meignin; Gérard Socié; Philippe Ratajczak; Anne Janin
Journal:  J Invest Dermatol       Date:  2013-09-04       Impact factor: 8.551

9.  Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation.

Authors:  M S Thakar; P Kurre; R Storb; M Kletzel; H Frangoul; M A Pulsipher; W Leisenring; M E D Flowers; B M Sandmaier; A Woolfrey; H-P Kiem
Journal:  Bone Marrow Transplant       Date:  2010-06-28       Impact factor: 5.483

Review 10.  The inherited bone marrow failure syndromes.

Authors:  S Deborah Chirnomas; Gary M Kupfer
Journal:  Pediatr Clin North Am       Date:  2013-12       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.